NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics on Thursday reported an 18 percent year-over-year increase in its second quarter revenues.

In a form 10-Q filed with the US Securities and Exchange Comission, the New York-based company, which went public in June, said that it had revenues of $1.3 million for the three months ended June 30,, compared to $1.1 million in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.